2023 World Conference on Lung Cancer (Posters)-P2.16. Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil

P2.16. Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil - PDF(Abstract)

Back to course

Pdf Summary

This document provides an overview of a presentation titled "Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil," which will be presented at the WCLC 2023 conference. The presentation will focus on small-cell lung cancer (SCLC) and neuroendocrine tumors. <br /><br />The main objective of the study is to evaluate the effectiveness and safety of durvalumab, in combination with platinum-etoposide, as a first-line treatment for extensive-stage SCLC (ES-SCLC) in Brazil. The CASPIAN study showed the benefit of durvalumab in improving survival rates, but there is limited real-world evidence on its effectiveness in Brazil. This study aims to collect data from medical charts to assess the efficacy and safety of durvalumab-based regimens in ES-SCLC patients in Brazil in a real-world setting.<br /><br />The study will include approximately 60 patients with ES-SCLC who have been treated with a durvalumab-based regimen. The primary objective is to characterize the demographic characteristics of the cohort. Secondary objectives include assessing progression-free survival (PFS), overall survival (OS), adverse events, discontinuation rates, and subgroup analyses. The study will follow patients for up to 24 months.<br /><br />The presentation emphasizes the importance of real-world evidence in supporting physicians, patients, payers, and other stakeholders in cancer care. Real-world studies provide validation of clinical trial data in a broader patient population, giving further information about the effectiveness of approved treatments.<br /><br />Keywords associated with the presentation include Durvalumab, Extensive Stage-Small Cell Lung Cancer, and Real-World. The presentation falls under the track of Small Cell Lung Cancer and Neuroendocrine Tumors and is categorized as a Clinical Trial in Progress abstract.<br /><br />Enrollment for the study is expected to start in June 2023 and close in June 2024.

Asset Subtitle

Mauro Zukin

Meta Tag

Speaker Mauro Zukin

Topic SCLC & Neuroendocrine Tumors: Trials in Progress

Keywords

Assessment

Efficacy

Safety

Durvalumab

Platinum-Etoposide

Previously Untreated

ES-SCLC

Brazil

Small-Cell Lung Cancer

Neuroendocrine Tumors